NetScientific (NSCI) Competitors GBX 56.84 +0.84 (+1.50%) (As of 05:57 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors NSCI vs. ETX, TRX, MTPH, COS, C4XD, DDDD, AREC, SBTX, SAR, and OKYOShould you be buying NetScientific stock or one of its competitors? The main competitors of NetScientific include e-therapeutics (ETX), Tissue Regenix Group (TRX), Biodexa Pharmaceuticals (MTPH), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Arecor Therapeutics (AREC), SkinBioTherapeutics (SBTX), Sareum (SAR), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry. NetScientific vs. e-therapeutics Tissue Regenix Group Biodexa Pharmaceuticals Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Arecor Therapeutics SkinBioTherapeutics Sareum OKYO Pharma e-therapeutics (LON:ETX) and NetScientific (LON:NSCI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Do analysts prefer ETX or NSCI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score e-therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ANetScientific 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility & risk, ETX or NSCI? e-therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, NetScientific has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Which has better earnings and valuation, ETX or NSCI? NetScientific has higher revenue and earnings than e-therapeutics. NetScientific is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioe-therapeutics£295K178.27-£10.06M-£0.02-450.00NetScientific£1.45M9.25-£2.64M-£0.11-509.09 Does the MarketBeat Community favor ETX or NSCI? e-therapeutics received 57 more outperform votes than NetScientific when rated by MarketBeat users. However, 69.61% of users gave NetScientific an outperform vote while only 60.09% of users gave e-therapeutics an outperform vote. CompanyUnderperformOutperforme-therapeuticsOutperform Votes12860.09% Underperform Votes8539.91% NetScientificOutperform Votes7169.61% Underperform Votes3130.39% Is ETX or NSCI more profitable? e-therapeutics has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat e-therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets e-therapeuticsN/A -38.75% -29.10% NetScientific -182.91%-13.70%-9.42% Does the media refer more to ETX or NSCI? In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled NetScientific'saverage media sentiment score. Company Overall Sentiment e-therapeutics Neutral NetScientific Neutral Do insiders and institutionals have more ownership in ETX or NSCI? 26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 14.7% of NetScientific shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by company insiders. Comparatively, 42.4% of NetScientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Summarye-therapeutics beats NetScientific on 7 of the 13 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Get NetScientific News Delivered to You Automatically Sign up to receive the latest news and ratings for NSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NSCI vs. The Competition Export to ExcelMetricNetScientificBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£13.41M£219.23M£5.59B£1.51BDividend YieldN/A3.54%4.31%11.15%P/E Ratio-509.09322.88135.821,705.20Price / Sales9.2512,067.921,548.07176,691.93Price / Cash6.1412.7738.0235.98Price / Book0.746.804.832.89Net Income-£2.64M-£26.18M£112.98M£163.45M7 Day Performance1.10%-0.30%5.65%4.91%1 Month Performance-4.27%3.55%9.52%-1.37%1 Year Performance-8.94%13.88%17.75%13.51% NetScientific Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETXe-therapeutics0 of 5 stars0.00 / 5 starsGBX 9-6.7%N/A-31.3%£52.59M£295,000.00-450.0035High Trading VolumeTRXTissue Regenix Group0 of 5 stars0.00 / 5 starsGBX 61+2.5%N/A+11.3%£43.45M£29.49M-3,050.00120MTPHBiodexa Pharmaceuticals0 of 5 stars0.00 / 5 starsGBX 18+1,794.7%N/A+0.0%£31.20M£645,000.00-21.9518Gap UpCOSCollagen Solutions plc (COS.L)0 of 5 stars0.00 / 5 starsGBX 6.63flatN/AN/A£30.99M£4.01M-8.283,350C4XDC4X Discovery0 of 5 stars0.00 / 5 starsGBX 12+27.3%N/A-33.3%£30.27M£24.68M300.0049News CoverageHigh Trading VolumeDDDD4D pharma0 of 5 stars0.00 / 5 starsGBX 16.66flatN/AN/A£30.05M£718,000.00-1.08106ARECArecor Therapeutics0 of 5 stars0.00 / 5 starsGBX 78.70-1.6%N/A-62.3%£29.72M£4.57M-281.0710SBTXSkinBioTherapeutics0 of 5 stars0.00 / 5 starsGBX 12.50+5.3%N/A-53.3%£28.26M£21,949.00-625.0011SARSareum0 of 5 stars0.00 / 5 starsGBX 26-7.1%N/AN/A£28.07M£47,204.00-433.333,211OKYOOKYO Pharma0 of 5 stars0.00 / 5 starsGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007Gap Down Related Companies and Tools Related Companies: e-therapeutics Competitors Tissue Regenix Group Competitors Biodexa Pharmaceuticals Competitors Collagen Solutions plc (COS.L) Competitors C4X Discovery Competitors 4D pharma Competitors Arecor Therapeutics Competitors SkinBioTherapeutics Competitors Sareum Competitors OKYO Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:NSCI) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NetScientific plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NetScientific With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
